News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,254 Results
Type
Article (40938)
Company Profile (267)
Press Release (681038)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204675)
Career Advice (2025)
Deals (35534)
Drug Delivery (111)
Drug Development (81388)
Employer Resources (173)
FDA (16419)
Job Trends (14947)
News (346414)
Policy (32732)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2571)
Accelerated approval (34)
Adcomms (24)
Allergies (144)
Alliances (49575)
ALS (170)
Alzheimer's disease (1676)
Antibody-drug conjugate (ADC) (314)
Approvals (16688)
Artificial intelligence (520)
Autoimmune disease (159)
Automation (42)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (174)
Bladder cancer (160)
Brain cancer (57)
Breast cancer (645)
Cancer (4857)
Cardiovascular disease (406)
Career advice (1710)
Career pathing (36)
CAR-T (283)
CDC (46)
Celiac Disease (2)
Cell therapy (749)
Cervical cancer (36)
Clinical research (69619)
Collaboration (1717)
Company closure (4)
Compensation (1172)
Complete response letters (57)
COVID-19 (2715)
CRISPR (93)
C-suite (863)
Cystic fibrosis (143)
Data (6296)
Decentralized trials (2)
Denatured (25)
Depression (135)
Diabetes (504)
Diagnostics (6711)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (255)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90261)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117414)
Executive appointments (981)
FDA (19565)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1480)
Gene editing (199)
Generative AI (44)
Gene therapy (597)
GLP-1 (967)
Government (4667)
Grass and pollen (6)
Guidances (384)
Healthcare (18881)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (60)
Indications (118)
Infectious disease (2991)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (254)
Interviews (316)
IPO (16643)
IRA (50)
Job creations (3643)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (547)
Leadership (32)
Legal (7951)
Liver cancer (91)
Longevity (15)
Lung cancer (657)
Lymphoma (382)
Machine learning (42)
Management (59)
Manufacturing (808)
MASH (164)
Medical device (13778)
Medtech (13834)
Mergers & acquisitions (19967)
Metabolic disorders (1274)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (321)
Neuropsychiatric disorders (89)
Neuroscience (2922)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4515)
Now hiring (68)
Obesity (598)
Opinion (263)
Ovarian cancer (167)
Pain (199)
Pancreatic cancer (230)
Parkinson's disease (284)
Partnered (33)
Patents (507)
Patient recruitment (497)
Peanut (57)
People (58917)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21703)
Phase 2 (30637)
Phase 3 (22827)
Pipeline (5437)
Policy (287)
Postmarket research (2564)
Preclinical (9203)
Press Release (64)
Prostate cancer (240)
Psychedelics (48)
Radiopharmaceuticals (283)
Rare diseases (846)
Real estate (5955)
Recruiting (70)
Regulatory (24549)
Reports (53)
Research institute (2391)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (148)
Series A (240)
Series B (191)
Service/supplier (11)
Sickle cell disease (97)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3615)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1013)
Venture capital (89)
Weight loss (381)
Women's health (93)
Worklife (18)
Date
Today (139)
Last 7 days (565)
Last 30 days (2328)
Last 365 days (29837)
2026 (3983)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54084)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (84)
Alaska (7)
Arizona (311)
Arkansas (13)
Asia (39238)
Australia (6415)
California (11394)
Canada (3318)
China (1103)
Colorado (480)
Connecticut (483)
Delaware (341)
Europe (84608)
Florida (1710)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (871)
India (69)
Indiana (527)
Iowa (22)
Japan (436)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1394)
Massachusetts (8153)
Michigan (327)
Minnesota (631)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3025)
New Mexico (28)
New York (3004)
North Carolina (1466)
North Dakota (8)
Northern California (5576)
Ohio (337)
Oklahoma (21)
Oregon (41)
Pennsylvania (2303)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (67)
South Dakota (1)
Southern California (4438)
Tennessee (177)
Texas (1755)
United States (40391)
Utah (340)
Vermont (1)
Virginia (264)
Washington D.C. (81)
Washington State (927)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
722,254 Results for "nanoviricides inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NanoViricides, Inc. Has Filed its Annual Report
October 1, 2025
·
15 min read
Press Releases
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
February 10, 2026
·
8 min read
Press Releases
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
February 12, 2026
·
11 min read
Press Releases
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
November 18, 2025
·
13 min read
Press Releases
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
October 28, 2025
·
11 min read
Press Releases
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
January 14, 2026
·
11 min read
Press Releases
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
November 13, 2025
·
8 min read
Press Releases
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
November 12, 2025
·
8 min read
Press Releases
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
November 4, 2025
·
14 min read
Business
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
NanoViricides, Inc. reports that it has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for our assets and platform technology.
May 23, 2024
·
9 min read
1 of 72,226
Next
